354 related articles for article (PubMed ID: 21288052)
1. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
3. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
5. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.
Lobello KW; Preskorn SH; Guico-Pabia CJ; Jiang Q; Paul J; Nichols AI; Patroneva A; Ninan PT
J Clin Psychiatry; 2010 Nov; 71(11):1482-7. PubMed ID: 20441720
[TBL] [Abstract][Full Text] [Related]
7. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
[TBL] [Abstract][Full Text] [Related]
8. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
[TBL] [Abstract][Full Text] [Related]
9. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
10. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
Hermann M; Hendset M; Fosaas K; Hjerpset M; Refsum H
Eur J Clin Pharmacol; 2008 May; 64(5):483-7. PubMed ID: 18214456
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
[TBL] [Abstract][Full Text] [Related]
13. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.
Eap CB; Lessard E; Baumann P; Brawand-Amey M; Yessine MA; O'Hara G; Turgeon J
Pharmacogenetics; 2003 Jan; 13(1):39-47. PubMed ID: 12544511
[TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of two formulations of venlafaxine extended-release 75-mg capsules in healthy brazilian male volunteers: A single-dose, randomized-sequence, open-label, two-period crossover study in the fasting and fed states.
Homero de Souza Filho J; Bonifácio FN; Bedor DC; Ramos VL; de Sousa CE; Sardón LL; Gonçalves TM; Moreira RC; Leal LB; de Santana DP
Clin Ther; 2010 Nov; 32(12):2088-96. PubMed ID: 21118744
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Malhotra B; Darsey E; Crownover P; Fang J; Glue P
Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
[TBL] [Abstract][Full Text] [Related]
17. Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
Jann MW; Spratlin V; Momary K; Zhang H; Turner D; Penzak SR; Wright A; VanDenBerg C
Eur J Clin Pharmacol; 2012 May; 68(5):715-21. PubMed ID: 22173281
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
19. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
[TBL] [Abstract][Full Text] [Related]
20. Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study.
Shi S; Liu Y; Wu J; Li Z; Zhao Y; Zhong D; Zeng F
Clin Ther; 2010 Oct; 32(11):1977-86. PubMed ID: 21095492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
